Phase II trial of perifosine +/- sorafenib in heavily pretreated patients with relapsed/refractory lymphomas

Trial Profile

Phase II trial of perifosine +/- sorafenib in heavily pretreated patients with relapsed/refractory lymphomas

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2014

At a glance

  • Drugs Perifosine (Primary) ; Sorafenib
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 11 Dec 2012 Final data were presented at the American Society of Hematology annual meeting, according to an Aeterna Zentaris Inc media release.
    • 26 Nov 2012 Status changed to completed based on information reported in an Aeterna Zentaris media release.
    • 26 Nov 2012 Final trial data will be presented at the 2012 Annual Meeting of the American Society of Hematology (ASH-2012) according to an Aeterna Zentaris media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top